Deal facts
- Buyer
- Chiesi Farmaceutici S.p.A.
- Target
- KalVista Pharmaceuticals, Inc.
- Deal value
- Not disclosed
- Announced
- 29 April 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Chiesi Farmaceutici S.p.A. has agreed to acquire KalVista Pharmaceuticals, Inc. in a going private transaction structured as a cash consideration deal. The Italian healthcare company announced the agreement on 29 April 2026, with the target being a US-based biotechnology firm operating within the healthcare sector. The transaction was completed on 11 June 2026, marking the end of the public listing for the acquired entity. No specific deal value was reported in the available data.
The acquisition represents a strategic move by the buyer to integrate the target's assets into its existing portfolio. This deal concludes the period during which KalVista Pharmaceuticals operated as an independent public company. The transaction is now final following the completion date.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Chiesi Farmaceutici S.p.A. completes acquisition of KalVista Pharmaceuticals, Inc.
Introductory Note On April 29, 2026, we previously reported with the U.S. Securities and Exchange Commission (the “SEC”) that KalVista Pharmaceuticals, Inc., a Delaware corporation (“ us ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated April 29, 2026, with Chiesi Farmaceutici S.p.A., an Italian società per azioni (“ Parent ”), Skyline Merger Sub
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
GlaxoSmithKline LLC to acquire Nuvalent, Inc.
GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…
- Buyer
- GlaxoSmithKline LLC
- Target
- Nuvalent, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
FONAR, LLC to acquire FONAR Corporation
FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…
- Buyer
- FONAR, LLC
- Target
- FONAR Corporation
- Deal value
- Not disclosed
- Deal type
- going private
Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.
Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…
- Buyer
- Zydus Worldwide DMCC
- Target
- Assertio Holdings, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Chiesi Farmaceutici S.p.A.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive